Dušan Leško, Juraj Bober
Chronic ulcerative colitis is an inflammatory bowel disease of unknown aetiology. It is conventionally treated with symptom-focused step-up therapy comprising ASA, corticosteroids, immunomodulators and biological therapy. Out of them infliximab and adalimumab are currently approved. Preoperative therapy may affect the incidence of postoperative complications. In an indicated case surgery is recommended. Total proctocolectomy and ileal pouch-anal anastomosis is a preferred operation. Prolonged medical biological treatment is associated with increase in treatment cost and risk of serious postoperative complications. They might influence the functional outcomes and durability of their IPAA.